EUVIMEDEUVIMED entdecken
Open Access

The management of Familial Pulmonary Fibrosis in different medical settings: Where does that leave us? An Italian nationwide survey.

Giorgio Monteleone, ILDs Study Group Sip/Irs, Laura Bergantini, Miriana D'Alessandro, Tommaso Pianigiani, Jacopo Simonetti, Bruno Iovene, Francesco Varone, Giacomo Sgalla, Luca Richeldi, Elena Bargagli, Paolo Cameli

Sarcoidosis vasculitis and diffuse lung diseases · 24.09.2024 · 41 (3) · e2024047-e2024047

DOI: 10.36141/svdld.v41i3.15744 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Sarcoidosis vasculitis and diffuse lung diseases, erschienen am 24.09.2024. Verfasst von Giorgio Monteleone und 11 weiteren Autor:innen. Beteiligte Einrichtung: Catholic University of Sacred Heart, Rome, Italy. Die Arbeit wurde bisher 8-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND AIM: Familial Pulmonary Fibrosis (FPF) is an emerging group of interstitial lung diseases (ILDs) caused by mutations mainly involving "telomere-related genes" and "surfactant-related genes". Although, in 2023, European Respiratory Society proposed a statement for FPFs management, these still remain a burden. Our work aimed to evaluate the management and impact of FPF in three Italian different medical settings: University Hospitals (UHs), non-University Hospitals (N-UHs) and outpatient clinics. METHODS: This survey was created by ILDs Study Group Società Italiana di Pneumologia/ Italian Respiratory Society (SIP-IRS) and diffused via email to all SIP-IRS members. The descriptive statistical analysis was conducted through GraphPad Prism software (version 8.0). Results: Twenty participants replied to the survey, of which 65% (13/20) worked at UH while the remaining 25% (6/20) and 5% (1/20) worked at N-UH and outpatient clinics, respectively. Centers with, at least, 150 ILD patients visits/year followed a higher number of FPF patients, regardless of University affiliation (p=0.0046). Despite significant discrepancies in genetic testing and availability of counselling were registered, no statistically significant differences in patients' anamnesis assessment were observed between UHs and N-UHs (p=0.4192 and p=0.6525). However, there were relevant differences in the number of FPF patients undergoing genetic assessment in the Centers with Genetics Lab or Unit inside the Hospital (p=0.0253). There was no consensus regarding the impact of FPF diagnosis on lung transplantation and screening of asymptomatic relatives. Similarly, no differences were reported in antifibrotic prescriptions between UHs and N-UHs. Although the typical UIP pattern was the most common radiological pattern observed in FPF patients, there were no differences in the prevalence of histopathological patterns between UH and N-UH. CONCLUSIONS: Improving pulmonologists' knowledge of the approach, diagnosis and management of FPF is a global medical topic. Scientific societies can provide significant support in raising physicians' awareness of this issue.

Schlagwörter

familial pulmonary fibrosisinterstitial lung diseasetelomere-related genesgenetic testinggenetic counselingantifibrotic therapylung transplantationhistopathological patternsusual interstitial pneumoniaphysician knowledge

Autor:innen und Institutionen

  • Catholic University of Sacred Heart, Rome, Italy.
  • Pulmonology Unit and Institute of Radiology, University of Trieste, Department of Medical Surgical and Health Sciences, Hospital of Cattinara, Trieste, Italy; UOC Pneumotisiology, Department of Clinical Medicine and Sur…
  • Respiratory Diseases Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
  • 2Respiratory Diseases Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
  • Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  • Catholic University of Sacred Heart, Rome, Italy; Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Zitieren

APA

Monteleone, G., ILDs Study Group Sip/Irs, Bergantini, L., D'Alessandro, M., Pianigiani, T., Simonetti, J., Iovene, B., Varone, F., Sgalla, G., Richeldi, L., Bargagli, E., & Cameli, P. (2024). The management of Familial Pulmonary Fibrosis in different medical settings: Where does that leave us? An Italian nationwide survey. Sarcoidosis vasculitis and diffuse lung diseases, 41(3), e2024047-e2024047. https://doi.org/10.36141/svdld.v41i3.15744

Vancouver

Monteleone G, ILDs Study Group Sip/Irs, Bergantini L, D'Alessandro M, Pianigiani T, Simonetti J, et al. The management of Familial Pulmonary Fibrosis in different medical settings: Where does that leave us? An Italian nationwide survey. Sarcoidosis vasculitis and diffuse lung diseases. 2024;41(3):e2024047-e2024047. doi:10.36141/svdld.v41i3.15744

BibTeX
@article{Monteleone2024,
  author = {Monteleone, Giorgio and ILDs Study Group Sip/Irs and Bergantini, Laura and D'Alessandro, Miriana and Pianigiani, Tommaso and Simonetti, Jacopo and Iovene, Bruno and Varone, Francesco and Sgalla, Giacomo and Richeldi, Luca and Bargagli, Elena and Cameli, Paolo},
  title = {The management of Familial Pulmonary Fibrosis in different medical settings: Where does that leave us? An Italian nationwide survey},
  journal = {Sarcoidosis vasculitis and diffuse lung diseases},
  year = {2024},
  volume = {41},
  number = {3},
  pages = {e2024047--e2024047},
  doi = {10.36141/svdld.v41i3.15744}
}
Kostenlos starten →